» Articles » PMID: 33516270

LncRNA APCDD1L-AS1 Induces Icotinib Resistance by Inhibition of EGFR Autophagic Degradation Via the MiR-1322/miR-1972/miR-324-3p-SIRT5 Axis in Lung Adenocarcinoma

Overview
Journal Biomark Res
Publisher Biomed Central
Date 2021 Jan 31
PMID 33516270
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Epidermal growth factor receptor-tyrosinase kinase inhibitor (EGFR-TKI) resistance is the major obstacle in the treatment of lung adenocarcinoma (LUAD) patients harboring EGFR-sensitive mutations. However, the long non-coding RNAs (lncRNAs) related to EGFR-TKIs resistance and their functional mechanisms are still largely unknown. This study aimed to investigate the role and regulatory mechanism of lncRNA APCDD1L-AS1 in icotinib resistance of lung cancer.

Methods: Molecular approaches including qRT-PCR, MTT assay, colony formation, RNA interference and cell transfection, RNA immunoprecipitation (RIP), dual luciferase reporter assay, RNA fluorescence in situ hybridization, TUNEL assay, flow cytometry, immunoblotting, xenograft model and transcriptome sequencing were used to investigate the mechanism of APCDD1L-AS1 in icotinib resistance.

Results: A novel lncRNA, APCDD1L-AS1 was identified as the most significantly upregulated lncRNA in icotinib-resistant LUAD cells by the transcriptome sequencing and differential lncRNA expression analysis. We found that APCDD1L-AS1 not only promoted icotinib resistance, but also upregulated the protein expression level of EGFR. Mechanistically, APCDD1L-AS1 promoted icotinib resistance and EGFR upregulation by sponging with miR-1322/miR-1972/miR-324-3p to remove the transcription inhibition of SIRT5. Furthermore, SIRT5 elevated EGFR expression and activation by inhibiting the autophagic degradation of EGFR, finally promoting icotinib resistance. Consistently, the autophagy initiator rapamycin could decrease EGFR levels and increase the sensitivity of icotinib-resistant LUAD cells to icotinib.

Conclusion: APCDD1L-AS1 could promote icotinib resistance by inhibiting autophagic degradation of EGFR via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis. The combination of autophagy initiator and EGFR-TKIs might serve as a potential new strategy for overcoming EGFR-TKIs resistance in LUAD patients.

Citing Articles

Silencing of LINC01278 promotes sensitivity of non-small cell lung cancer cells to osimertinib by targeting miR-324-3p/ZFX axis.

Lei Q, Liu P, Guan X, Liu L, He W Cytotechnology. 2024; 77(1):23.

PMID: 39711969 PMC: 11659544. DOI: 10.1007/s10616-024-00673-8.


ZNF460-mediated upregulation of APCDD1L-DT promotes cholangiocarcinoma development by inhibiting the ubiquitin-mediated degradation of DVL2.

Gao X, Zou X, Guan C, Sha X, Liu S, Zhang X Cancer Gene Ther. 2024; 31(10):1585-1597.

PMID: 39210030 DOI: 10.1038/s41417-024-00826-z.


Cervical cancer-specific long non-coding RNA landscape reveals the favorable prognosis predictive performance of an ion-channel-related signature model.

Wang B, Wang W, Zhou W, Zhao Y, Liu W Cancer Med. 2024; 13(11):e7389.

PMID: 38864475 PMC: 11167610. DOI: 10.1002/cam4.7389.


Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.

Hong S, Zhang Y, Wang D, Wang H, Zhang H, Jiang J Aging (Albany NY). 2024; 16(11):9972-9989.

PMID: 38862217 PMC: 11210254. DOI: 10.18632/aging.205911.


Analysis of Human microRNA Expression Profiling During Diquat-Induced Renal Proximal Tubular Epithelial Cell Injury.

Chen Y, Li H, Liu J, Jiang D, Zheng H, Dong X J Inflamm Res. 2023; 16:4953-4965.

PMID: 37927960 PMC: 10625323. DOI: 10.2147/JIR.S427004.


References
1.
Wang J, Jia Y, Zhao S, Zhang X, Wang X, Han X . BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer. Oncogene. 2017; 36(45):6235-6243. DOI: 10.1038/onc.2017.217. View

2.
Dong Y, Gong W, Hua Z, Chen B, Zhao G, Liu Z . Combination of Rapamycin and MK-2206 Induced Cell Death Autophagy and Necroptosis in MYCN-Amplified Neuroblastoma Cell Lines. Front Pharmacol. 2020; 11:31. PMC: 7033642. DOI: 10.3389/fphar.2020.00031. View

3.
Xiang M, Jiang H, Shu Y, Chen Y, Jin J, Zhu Y . Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis. Int J Biol Sci. 2020; 16(9):1536-1550. PMC: 7097919. DOI: 10.7150/ijbs.40042. View

4.
Feng C, Zhao Y, Li Y, Zhang T, Ma Y, Liu Y . LncRNA MALAT1 Promotes Lung Cancer Proliferation and Gefitinib Resistance by Acting as a miR-200a Sponge. Arch Bronconeumol (Engl Ed). 2019; 55(12):627-633. DOI: 10.1016/j.arbres.2019.03.026. View

5.
Shih J, Gow C, Yang P . EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med. 2005; 353(2):207-8. DOI: 10.1056/NEJM200507143530217. View